<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6296">
  <stage>Registered</stage>
  <submitdate>30/01/2017</submitdate>
  <approvaldate>30/01/2017</approvaldate>
  <nctid>NCT03038776</nctid>
  <trial_identification>
    <studytitle>Recombinant H7 Hemagglutinin Influenza Vaccine Trial</studytitle>
    <scientifictitle>A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine</scientifictitle>
    <utrn />
    <trialacronym>FLU007</trialacronym>
    <secondaryid>FLU007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza, Avian</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Recombinant influenza hemagglutinin

Experimental: 1 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)

Experimental: 2 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant

Experimental: 3 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant

Experimental: 4 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen

Experimental: 5 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant

Experimental: 6 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant


Other interventions: Recombinant influenza hemagglutinin
Avian H7N9 influenza vaccine

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Seroconversion</outcome>
      <timepoint>1 month post immunization</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Seroprotection</outcome>
      <timepoint>1 month post immunization</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Fold rise in geometric mean titer</outcome>
      <timepoint>1 month post immunization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Frequency and severity of adverse events - Frequency and severity of adverse events</outcome>
      <timepoint>12 months post immunization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>T cell response - Frequency of influenza specific T cells</outcome>
      <timepoint>1 month post-immunization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female

          -  Age 18 years or over

          -  Able to provide written informed consent

          -  Willing and able to comply with the protocol for the duration of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of serious vaccine allergy*

          -  History of vasculitis, Wegener's granulomatosis, narcolepsy, Guillain Barre, SLE or
             other systemic autoimmune disease that in the opinion of the investigator would make
             the vaccine contraindicated

          -  History of chronic liver disease or liver transaminases elevated more than 3xULN

          -  Women of childbearing potential, unless using a reliable and appropriate contraceptive
             method, specifically oral contraceptive pill, IUD or mechanical barrier device.

          -  Pregnant or lactating women.

          -  Any serious medical, social or mental condition which, in the opinion of the
             investigator, would be detrimental to the subjects or the study.

          -  Receipt of another investigational agent within 28 days preceding initiation of
             treatment.

               -  Individuals who have a past history of potential vaccine reactions will be
                  assessed by the investigator, who will decide whether any past potential
                  vaccine-related side are sufficiently minimal to allow vaccine administration to
                  proceed.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders University - Adelaide</hospital>
    <postcode>5042 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian Respiratory and Sleep Medicine Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Recombinant H7 (rH7) vaccine has been shown to be poorly immunogenic in previous human
      clinical trials. This study will test approaches to improve the immunogenicity of H7 vaccine,
      namely use of a three dose regimen, use of a modified H7 HA sequence from which the Tregitope
      has been removed (rH7m), and inclusion of delta inulin adjuvant adjuvant in the vaccine</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03038776</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dimitar Sajkov, MD, PhD</name>
      <address>Flinders University/ARASMI</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kathrina Bartolay, RN</name>
      <address />
      <phone>0882044572</phone>
      <fax />
      <email>kathrina.bartolay@sa.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>